A Phase 3 interventional study of Methylprednisolone and Prednisone in Rejection; Transplant, Kidney and Rejection; Transplant, Pancreas, sponsored by University of Sydney. Recruiting at 30 sites in 3 countries. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2026-08-31.
Sponsored by University of Sydney · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
After a kidney or a kidney-pancreas transplant, some patients may face problems with their new organs. This happens because the body sometimes makes a mistake and tries to get rid of the organ. This problem is called rejection. One type of rejection is known as Acute T cell mediated rejection (TCMR). This can lead to many problems or even stop the transplant from working.
Doctors give strong steroids to treat this problem, but there are no rules for how much steroid to give. Too much steroids can cause problems like heart and bone problems, bad infections, and weight gain. That is why we need to find the right dose of steroids for each person to treat this.
TACKLE-IT is a study that will try to find the right steroid dose for treating rejection.
TACKLE-IT is an international, multi-centre, 2x2 factorial, PROBE-style, registry-embedded randomised controlled trial (RCT) that compares the effectiveness and safety of high vs low dose IV MP, and high vs low dose oral prednisone taper as the first-line therapy for acute TCMR in kidney and SPK transplant recipients. This RCT was conceived and developed through extensive consultation and collaboration with our key stakeholders, including transplant recipients with lived experience and the International TCMR Working Group with sponsorship by 4 international transplant societies (The Transplantation Society (TTS), American Society of Transplantation (AST), European Society of Transplantation (ESOT) and Transplant Society of Australia and New Zealand (TSANZ). TACKLE-IT is led by an international multi-disciplinary team of transplant health professionals, clinical trialists, biostatisticians, health economist, social scientist, consumers.
TACKLE-IT will address the critical unmet need and resolve a decades-long unanswered question, 'What is the minimally acceptable, safe and effective steroid dose for the treatment of acute TCMR in kidney and SPK transplant recipients?'
University of Sydney is the lead sponsor of 94 studies on the registry; 26 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
All children (aged 2+ years) and adults who have received a kidney or SPK transplant with proven *acute TCMR (≥ Banff borderline (minimum i1 score) whether clinical or subclinical).
Individuals with the following are eligible for inclusion:
i. Concurrent acute TCMR and microvascular inflammation (MVI) defined as g+ptc, but without ABMR diagnosis.
ii. Concurrent acute TCMR and chronic active TCMR.
Exclusion Criteria:
Individuals meeting any of the following criteria will be excluded from participation:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Lower dose IV MP (250 mg daily x 3 days in adults or 150 mg/m² daily x 3, or to a max 250 mg/dose in children (\<18 years), with lower dose (25mg daily x 7 days, or 15mg/m² x 7 days, or to a max 25mg/dose for those \< 18 years ) oral prednisone augmentation then return to standard prednisone.
Drug: Methylprednisolone · Drug: Prednisone
Lower dose IV MP (250 mg daily x 3 in adults or 150 mg/m² daily x 3, or to a max 250 mg/dose in children (\<18 years), with higher dose (50mg daily x 7, or 30mg/m² daily x 7, or to a max 50mg/dose for those \< 18 years) oral prednisone augmentation then return to standard prednisone.
Drug: Methylprednisolone · Drug: Prednisone
Higher dose IV MP (500mg daily x 3 in adults or 300 mg/m² daily x 3 or to a max 500 mg/dose in children (\<18 years), with lower dose (25mg daily x 7 days, or 15mg/m² daily x 7 days, or to a max 25mg/dose for those \< 18 years) oral prednisone augmentation then return to standard prednisone.
Drug: Methylprednisolone · Drug: Prednisone
Higher dose IV MP (500 mg daily x 3 in adults or 300 mg/m² daily x 3 or to a max 500 mg/dose in children (\<18 years), with higher dose (50mg daily x 7 days, or 30mg/m² daily x 7 days, or to a max 50mg/dose for those \< 18 years) oral prednisone augmentation, then return to standard prednisone.
Drug: Methylprednisolone · Drug: Prednisone
IV Methylprednisolone
Also known as: IV MP
Oral prednisone augmentation
Histological resolution of biopsy-proven acute rejection
Histological resolution of biopsy-proven acute rejection is defined by the absence of any biopsy proven acute rejection (BPAR) on follow-up biopsy, including Banff Borderline (i1 t1), mixed rejection, ABMR and chronic active TCMR using Banff 2022 criteria.
Time frame: 12 weeks post-randomization
Improvement in allograft function for clinical rejection; and defined by an average of at least 2 serum creatinine at baseline and at least 2 serum creatinine from 11-13 weeks
Reduction in serum creatinine ≥20% is defined as the relative reduction in serum creatinine from baseline and at 11-13 weeks after randomisation, in the absence of dialysis or achieving freedom from dialysis. Staff are required to record the serum creatinine at each visit; or dates and modality of dialysis initiation and / or discontinuation.
Time frame: 11 to 13 weeks post-randomization
Avoidance of rescue therapies within 12 weeks post-randomization to achieve histological resolution and/or improvement in allograft function
Use of rescue therapy is defined as: the use of any adjunctive T and B cell depleting therapies such as intravenous thymoglobulin, alemtuzumab, bortezomib, or rituximab, or additional doses of IV MP within the first 12 weeks after randomisation.
Time frame: 12 weeks post-randomization
All cause death and death-censored graft loss
All cause death and death-censored graft loss have been identified as the core outcomes for kidney transplant recipients. However, death and death-censored graft loss are anticipated to have a very low incidence at the 12 weeks post-randomization primary outcome ascertainment and were therefore not included in the primary composite outcome. They will be reported as principal secondary endpoints. All-cause death also includes cause-specific death (infections, cancers, cardiovascular-related, and other causes of death) at 12 weeks after randomisation.
Time frame: At 12 weeks post-randomization
Estimated glomerular filtration rate (eGFR)
* Absolute eGFR (2021 CKD-EPI eGFR without race modifier for adults, and the CKiD U25 equation to estimate GFR in children \<18 years) 12, 24 and 48 weeks. * Decline in eGFR (slope) from randomization to 48 weeks.
Time frame: At 12, 24 and 48 weeks post-randomization
Urine albumin: creatinine ratios
Urine ACR is measured as standard of care. Rationale: ACR screens for graft dysfunction and is a marker for graft outcomes
Time frame: At 12, 24 and 48 weeks post-randomization
Trajectories of serum creatinine changes
Time frame: From randomization to 48 weeks post-randomization
Development of acute antibody mediated rejection (ABMR) and mixed rejection (concomitant ABMR + TCMR)
Development of acute antibody mediated rejection (ABMR) and mixed rejection (concomitant ABMR + TCMR) within 48 weeks after randomisation. ABMR and mixed rejection are defined according to the Banff 2022 criteria
Time frame: 48 weeks post-randomization
Development of chronic fibrosis in the allograft
Development of chronic fibrosis in the allograft. This is defined as the absolute (Banff ci+ctscores) at 12 weeks
Time frame: Baseline to 12 weeks post-randomization
Infections (all types and sites)
All types and number of events related to infections that required antimicrobials and hospitalisation for infections will be recorded.
Time frame: Anytime from randomization to 48 weeks post-randomization
Quality of life (QoL)
QoL will be assessed using the EuroQol-5 Dimension-5 Level (EQ-5D-5L) for adult participants (aged ≥18 years). For paediatric participants (aged 2-17 years), age-appropriate versions of the EuroQol Youth version (EQ-5D-Y) will be used as follows: * Ages 2-7: EQ-5D-Y proxy version * Ages 8-17: EQ-5D-Y self-report version Both the EQ-5D-5L and EQ-5D-Y report utility scores ranging from -0.281 to 1 (EQ-5D-5L UK value set) and -0.109 to 1 (EQ-5D-Y, proxy or self-report), where 1 represents perfect health, 0 represents a health state equivalent to death, and negative scores represent health states worse than death. Higher scores indicate better health-related quality of life.
Time frame: Baseline (at randomization), 12 weeks , 24 weeks , and 48 weeks post-randomization
Cancer
All types and sites
Time frame: Anytime from randomization to 48 weeks
Steroid-related adverse effects
Adaption from the Steroid Patient Reported Outcome (Steroid PRO).
Time frame: 3 days post randomisation, 7 days post randomisation, week 12 post-randomisation, week 24 post-randomisation and week 48 post-randomisation
Integrative Box Risk Prediction Score (iBOX)
Graft survival prediction will be assessed using the Integrative Box Risk Prediction Score (iBOX), a validated composite risk prediction tool for kidney transplant outcomes. The iBOX score integrates clinical, functional, and immunological parameters including serum creatinine, proteinuria, biopsy findings, and presence of donor-specific antibodies to estimate the risk of allograft failure. The iBox score essentially assigns a numerical value based on these parameters, indicating the risk of allograft loss (kidney transplant failure).
Time frame: Week 13 to week 48 post-randomisation
Economic evaluation: Incremental costs and benefits
Incremental costs and benefits (life years and quality adjusted life years gained) between the two treatment arms.
Time frame: During the 52-week follow up period
Process evaluation: patients' and clinicians' perspectives on the treatment of acute TCMR
Semi-structured interviews will be conducted to elicit patients' perspectives and experiences of having acute TCMR, the adverse effects of the treatments. Health professionals' will also be interviewed to elicit their perspectives and experiences regarding the barriers, challenges, and enablers for implementing the intervention, the perceived benefits, and harms of the intervention and how the intervention should be delivered such that maximal interactions of the intervention are reached for the intended participants.
Time frame: Anytime between week 12 and 48 of the trial
Transplant biobank - analysis of TCMR treatment responders vs non-responders
To characterise and compare the T cell receptor (TCR) repertoire in transplant recipients who were responsive and not responsive to the various corticosteroid dosing strategies in acute TCMR. 1. T cell receptor repertoire (Australia) 2. Urine chemokines (Canada) 3. HLA eplet analysis (Canada) 4. Biopsy transcriptomics (B-HOT panel, Canada)
Time frame: Week 13 to week 48 post-randomization
Life participation
Life participation will be assessed using the Patient-Reported Outcomes Measurement Information System (PROMIS®) Ability to Participate in Social Roles and Activities - Short Form 4a (SF4a). This instrument measures perceived ability to perform usual social roles and activities. Scores are reported as T-scores standardized to the general U.S. population (mean = 50, SD = 10). * Minimum score: 20 * Maximum score: 80 Higher scores indicate better ability to participate in social roles and activities (i.e., a more favorable outcome).
Time frame: Randomisation, week 12 post-randomization, week 24 post-randomization and week 48 post-randomization
Transplant fibrosis ultrasound analysis
Correlation of ultrasound images collected at the time of kidney biopsy with histologic and clinical parameters (Canadian and Australian participating centers)
Time frame: Week 13 to week 48 post-randomization
Plan to share: Yes — The data collected for the study, including individual patient data and a data dictionary that defines each field in the data set, will be made available as deidentified participant data to researchers who propose to use the data for individual patient data meta-analysis. Data will be shared following approval of the proposal by the corresponding author and a signed data access agreement, beginning 2 years following main publication.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Study protocol, SAP, ICF will be provided 3 months after registration. The Clinical study report and code will be provided after completion of the trial.
Access criteria: All IPD data arising from the trial will be shared 2 years after publication of the main results.
Started Mar 2026 (actual). Primary completion is estimated for Jun 2030, 51 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Methylprednisolone · Prednisone
Rejection, Psychology
University of Sydney